Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


VEGF receptor-1 modulates amyloid β 1-42 oligomer-induced senescence in brain endothelial cells.

Singh Angom R, Wang Y, Wang E, Pal K, Bhattacharya S, Watzlawik JO, Rosenberry TL, Das P, Mukhopadhyay D.

FASEB J. 2019 Mar;33(3):4626-4637. doi: 10.1096/fj.201802003R. Epub 2018 Dec 21.


ABCA7 loss-of-function variants, expression, and neurologic disease risk.

Allen M, Lincoln SJ, Corda M, Watzlawik JO, Carrasquillo MM, Reddy JS, Burgess JD, Nguyen T, Malphrus K, Petersen RC, Graff-Radford NR, Dickson DW, Ertekin-Taner N.

Neurol Genet. 2017 Jan 5;3(1):e126. doi: 10.1212/NXG.0000000000000126. eCollection 2017 Feb.


Human class I major histocompatibility complex alleles determine central nervous system injury versus repair.

Wootla B, Denic A, Watzlawik JO, Warrington AE, Zoecklein LJ, Papke-Norton LM, David C, Rodriguez M.

J Neuroinflammation. 2016 Nov 17;13(1):293.


A human anti-polysialic acid antibody as a potential treatment to improve function in multiple sclerosis patients.

Watzlawik JO, Painter MM, Wootla B, Rodriguez M.

J Nat Sci. 2015 Aug;1(8). pii: e141.


Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study.

Watzlawik JO, Kahoud RJ, Wootla B, Painter MM, Warrington AE, Carey WA, Rodriguez M.

J Vis Exp. 2016 Jun 29;(112). doi: 10.3791/54139.


Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Wootla B, Watzlawik JO, Stavropoulos N, Wittenberg NJ, Dasari H, Abdelrahim MA, Henley JR, Oh SH, Warrington AE, Rodriguez M.

Expert Opin Biol Ther. 2016 Jun;16(6):827-839. doi: 10.1517/14712598.2016.1158809. Epub 2016 Mar 10. Review.


Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression.

Watzlawik JO, Wootla B, Rodriguez M.

Curr Pharm Des. 2016;22(8):1049-59. Review.


Tryptophan Metabolites and Their Impact on Multiple Sclerosis Progression.

Watzlawik JO, Wootla B, Rodriguez M.

Curr Pharm Des. 2015 Dec 14. [Epub ahead of print]


Antiviral Protection via RdRP-Mediated Stable Activation of Innate Immunity.

Painter MM, Morrison JH, Zoecklein LJ, Rinkoski TA, Watzlawik JO, Papke LM, Warrington AE, Bieber AJ, Matchett WE, Turkowski KL, Poeschla EM, Rodriguez M.

PLoS Pathog. 2015 Dec 3;11(12):e1005311. doi: 10.1371/journal.ppat.1005311. eCollection 2015 Dec.


Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease.

Wootla B, Denic A, Watzlawik JO, Warrington AE, Rodriguez M.

Mol Neurobiol. 2016 Oct;53(8):5217-28. doi: 10.1007/s12035-015-9436-3. Epub 2015 Sep 26. Review.


Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.

Wootla B, Watzlawik JO, Warrington AE, Wittenberg NJ, Denic A, Xu X, Jordan LR, Papke LM, Zoecklein LJ, Pierce ML, Oh SH, Kantarci OH, Rodriguez M.

JAMA Neurol. 2015 Nov;72(11):1346-53. doi: 10.1001/jamaneurol.2015.2188. Review.


Abbreviated exposure to hypoxia is sufficient to induce CNS dysmyelination, modulate spinal motor neuron composition, and impair motor development in neonatal mice.

Watzlawik JO, Kahoud RJ, O'Toole RJ, White KA, Ogden AR, Painter MM, Wootla B, Papke LM, Denic A, Weimer JM, Carey WA, Rodriguez M.

PLoS One. 2015 May 28;10(5):e0128007. doi: 10.1371/journal.pone.0128007. eCollection 2015.


Polysialic acid as an antigen for monoclonal antibody HIgM12 to treat multiple sclerosis and other neurodegenerative disorders.

Watzlawik JO, Kahoud RJ, Ng S, Painter MM, Papke LM, Zoecklein L, Wootla B, Warrington AE, Carey WA, Rodriguez M.

J Neurochem. 2015 Sep;134(5):865-78. doi: 10.1111/jnc.13121. Epub 2015 Apr 27.


Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Watzlawik JO, Wootla B, Painter MM, Warrington AE, Rodriguez M.

Expert Rev Neurother. 2013 Sep;13(9):1017-29. doi: 10.1586/14737175.2013.835601. Review.


A patterned recombinant human IgM guides neurite outgrowth of CNS neurons.

Xu X, Wittenberg NJ, Jordan LR, Kumar S, Watzlawik JO, Warrington AE, Oh SH, Rodriguez M.

Sci Rep. 2013;3:2267. doi: 10.1038/srep02267.


The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment.

Wootla B, Watzlawik JO, Denic A, Rodriguez M.

Expert Rev Clin Immunol. 2013 Jun;9(6):535-49. doi: 10.1586/eci.13.37. Review.


PDGF is required for remyelination-promoting IgM stimulation of oligodendrocyte progenitor cell proliferation.

Watzlawik JO, Warrington AE, Rodriguez M.

PLoS One. 2013;8(2):e55149. doi: 10.1371/journal.pone.0055149. Epub 2013 Feb 1.

Supplemental Content

Loading ...
Support Center